Patents by Inventor Ellen Border

Ellen Border has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • T cell receptors
    Patent number: 11203627
    Abstract: The present invention relates to T cell receptors (TCRs) which bind the HLA-A*02 restricted peptide GLYDGMEHL (SEQ ID NO: 1) derived from the MAGE-A10 protein. The TCRs of the invention demonstrate excellent specificity profiles for this MAGE epitope. Also provided are nucleic acids encoding the TCRs, cells engineered to present the TCRs, cells harbouring expression vectors encoding the TCRs and pharmaceutical compositions comprising the TCRs, nucleic acids or cells of the invention.
    Type: Grant
    Filed: April 5, 2017
    Date of Patent: December 21, 2021
    Assignee: ADAPTIMMUNE LIMITED
    Inventors: Conor Hayes, Arsen Volkov, Andrew Gerry, Ellen Border, Edward Carter
  • T CELL RECEPTORS
    Publication number: 20180208638
    Abstract: The present invention relates to T cell receptors (TCRs) which bind the HLA-A*02 restricted peptide GLYDGMEHL (SEQ ID NO: 1) derived from the MAGE-A10 protein. The TCRs of the invention demonstrate excellent specificity profiles for this MAGE epitope. Also provided are nucleic acids encoding the TCRs, cells engineered to present the TCRs, cells harbouring expression vectors encoding the TCRs and pharmaceutical compositions comprising the TCRs, nucleic acids or cells of the invention.
    Type: Application
    Filed: April 5, 2017
    Publication date: July 26, 2018
    Inventors: Conor Hayes, Arsen Volkov, Andrew Gerry, Ellen Border, Edward Carter
  • T CELL RECEPTORS
    Publication number: 20170218043
    Abstract: The present invention relates to T cell receptors (TCRs) which bind the HLA-A*02 restricted peptide GLYDGMEHL (SEQ ID NO: 1) derived from the MAGE-A10 protein. The TCRs of the invention demonstrate excellent specificity profiles for this MAGE epitope. Also provided are nucleic acids encoding the TCRs, cells engineered to present the TCRs, cells harbouring expression vectors encoding the TCRs and pharmaceutical compositions comprising the TCRs, nucleic acids or cells of the invention.
    Type: Application
    Filed: April 5, 2017
    Publication date: August 3, 2017
    Inventors: Conor Hayes, Arsen Volkov, Andrew Gerry, Ellen Border, Edward Carter